Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143217 | 0.88 | SIGMAR1 (0.48) | SIGMAR1CYP2D6ALDH1A1CYP1A2HRH3 | |
| SCHEMBL446112 | 0.86 | SIGMAR1 (0.50) | SIGMAR1CYP2D6ALDH1A1CYP1A2HRH3 | |
| SCHEMBL12006407 | 0.82 | SIGMAR1 (0.50) | SIGMAR1POLBKMT2AALDH1A1MAPK1 | |
| SCHEMBL29973392 | 0.82 | SIGMAR1 (0.50) | SIGMAR1POLBKMT2AALDH1A1MAPK1 | |
| SCHEMBL15306596 | 0.81 | SIGMAR1 (0.57) | SIGMAR1CYP3A4CYP2D6POLBKMT2A | |
| SCHEMBL18940355 | 0.79 | SIGMAR1 (0.44) | SIGMAR1POLBKMT2AALDH1A1MAPK1 | |
| SCHEMBL23964434 | 0.74 | SIGMAR1 (0.52) | SIGMAR1CYP3A4CYP2D6POLBKMT2A | |
| SCHEMBL12005459 | 0.73 | SIGMAR1 (0.46) | SIGMAR1POLBKMT2AMEN1KEAP1 | |
| SCHEMBL3378557 | 0.72 | HTR1D (0.67) | HTR1DHTR1B | |
| SCHEMBL427834 | 0.71 | L3MBTL1 (0.60) | SIGMAR1ALDH1A1HRH3SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751136-B1 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-1751136-B1 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-1537084-B1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8476434-B2 | Protein kinase modulators and method of use | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476434-B2 | Protein kinase modulators and method of use | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476434-B2 | Protein kinase modulators and method of use | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | SIGMAR1 2397/4885CYP3A4 67/4885CYP2D6 41/4885 |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | SIGMAR1 1627/4885CYP3A4 373/4885CYP2D6 256/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | SIGMAR1 2397/4885CYP3A4 67/4885CYP2D6 41/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | SIGMAR1 2397/4885CYP3A4 67/4885CYP2D6 41/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | SIGMAR1 1803/4885CYP3A4 385/4885CYP2D6 310/4885 |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | GRK4, MAP4K5, GRK5 | SIGMAR1 3327/4885CYP3A4 1882/4885CYP2D6 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.